Institutional members access full text with Ovid®

New SSRI Approved

Aschenbrenner, Diane S. MS, RN

AJN, American Journal of Nursing: May 2011 - Volume 111 - Issue 5 - p 21
doi: 10.1097/01.NAJ.0000398044.92675.7a
Drug Watch
Online Continuing Education

* A new selective serotonin reuptake inhibitor, vilazodone hydrochloride (Viibryd), has been approved for the treatment of depression.

* Vilazodone's mechanism of action is similar to that of other drugs in the class, and it carries similar warnings and precautions.

* Vilazodone should be taken with food, which increases its bioavailability.

Diane S. Aschenbrenner is the course coordinator for undergraduate pharmacology at Johns Hopkins University School of Nursing in Baltimore, MD. She also coordinates Drug Watch:

© 2011 Lippincott Williams & Wilkins, Inc.